Q-omics provides the consensus-scored AEN profile across patient tissues and cancer cell-line models. AEN expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, AEN is differentially expressed in 17, with the highest sampling consensus in COAD. Additionally, AEN RNA expression shows 18,559 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LGG, COAD, and UVM as cancer lineages where AEN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AEN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AEN survival associations across molecular data types. AEN RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AEN RNA expression–survival associations across cancer types. High AEN expression shows unfavorable associations in LGG, MESO and BLCA, but favorable associations in KIRC, LIHC and STAD. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for AEN RNA expression.
This table summarizes AEN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for AEN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AEN shows higher tumor expression in COAD, KIRC, HNSC, KIRP, LIHC and STAD. The COAD box plot shows higher AEN RNA expression in tumor versus normal tissue (log2 FC = +2.009, t-test p < 0.001).
This table shows molecular features associated with AEN in patient tissues and cancer cell lines. In patient samples, AEN shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, AEN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and UPPER_AERODIGESTIVE_TRACT.
